Elucidating the role of MICAL1 in pan-cancer using integrated bioinformatics and experimental approaches

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. Ca A Cancer J Clinicians. 2023;73(1):17–48. doi: 10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Suzuki T, Nakamoto T, Ogawa S, et al. MICAL, a novel CasL interacting molecule, associates with vimentin. J Biol Chem. 2002;277(17):14933–14941. doi: 10.1074/jbc.M111842200
   PubMed Web of Science ®Google Scholar
• Haikazian S, Olson MF. MICAL1 monooxygenase in autosomal dominant lateral temporal epilepsy: role in Cytoskeletal Regulation and relation to cancer. Genes (Basel). 2022;13(5):715. doi: 10.3390/genes13050715
   PubMed Web of Science ®Google Scholar
• Fischer J, Weide T, Barnekow A. The MICAL proteins and rab1: a possible link to the cytoskeleton? Biochem Biophys Res Commun. 2005;328(2):415–423. doi: 10.1016/j.bbrc.2004.12.182
   PubMed Web of Science ®Google Scholar
• Esposito A, Ventura V, Petoukhov MV, et al. Human MICAL1: activation by the small GTPase Rab8 and small-angle X-ray scattering studies on the oligomerization state of MICAL1 and its complex with Rab8. Protein Sci. 2019;28(1):150–166. doi: 10.1002/pro.3512
   PubMed Web of Science ®Google Scholar
• Pasterkamp RJ, Dai HN, Terman JR, et al. MICAL flavoprotein monooxygenases: expression during neural development and following spinal cord injuries in the rat. Mol Cell Neurosci. 2006;31(1):52–69. doi: 10.1016/j.mcn.2005.09.001
   PubMed Web of Science ®Google Scholar
• Giridharan SS, Rohn JL, Naslavsky N, et al. Differential regulation of actin microfilaments by human MICAL proteins. J Cell Sci. 2012;125(Pt 3):614–624. doi: 10.1242/jcs.089367
   PubMed Web of Science ®Google Scholar
• Alto LT, Terman JR. MICALs. Curr Biol. 2018 May 7;28(9):R538–r541. doi: 10.1016/j.cub.2018.01.025
   Web of Science ®Google Scholar
• Giridharan SS, Caplan S. MICAL-family proteins: complex regulators of the actin cytoskeleton. Antioxid Redox Signaling. 2014;20(13):2059–2073. doi: 10.1089/ars.2013.5487
   PubMed Web of Science ®Google Scholar
• Konstantinidis K, Bezzerides VJ, Lai L, et al. MICAL1 constrains cardiac stress responses and protects against disease by oxidizing CaMKII. J Clin Investig. 2020;130(9):4663–4678. doi: 10.1172/JCI133181
   PubMed Web of Science ®Google Scholar
• Xu C, Mao L, Tian H, et al. MICAL1 (molecule interacting with CasL 1) protects oligodendrocyte cells from oxidative injury through regulating apoptosis, autophagy in spinal cord injury. Neurosci lett. 2021;750:135712. doi: 10.1016/j.neulet.2021.135712
   PubMed Web of Science ®Google Scholar
• Cai K, Deng L, Zheng D, et al. MICAL1 facilitates pancreatic cancer proliferation, migration, and invasion by activating WNT/β-catenin pathway. J Transl Med. 2022;20(1):528. doi: 10.1186/s12967-022-03749-1
   PubMed Web of Science ®Google Scholar
• Deng W, Wang Y, Zhao S, et al. MICAL1 facilitates breast cancer cell proliferation via ROS-sensitive ERK/cyclin D pathway. J Cell Mol Med. 2018;22(6):3108–3118. doi: 10.1111/jcmm.13588
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the xena platform. Nature Biotechnol. 2020;38(6):675–678. doi: 10.1038/s41587-020-0546-8
   PubMed Web of Science ®Google Scholar
• Tomczak K, Czerwińska P, Wiznerowicz M. The cancer genome atlas (TCGA): an immeasurable source of knowledge, contemporary oncology (Poznan, Poland. Współczesna Onkologia. 2015;19(1):A68–77. doi: 10.5114/wo.2014.47136
   Google Scholar
• Chandrashekar DS, Karthikeyan SK, Korla PK, et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia (New York, NY). 2022;25:18–27. doi: 10.1016/j.neo.2022.01.001
   PubMed Web of Science ®Google Scholar
• Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5(9):1315–1316. doi: 10.1097/JTO.0b013e3181ec173d
   PubMed Web of Science ®Google Scholar
• von Mering C, Huynen M, Jaeggi D, et al. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258–261. doi: 10.1093/nar/gkg034
   PubMed Web of Science ®Google Scholar
• Franz M, Rodriguez H, Lopes C, et al. GeneMANIA update 2018. Nucleic Acids Res. 2018;46(W1):W60–w64. doi: 10.1093/nar/gky311
   PubMed Web of Science ®Google Scholar
• Kuleshov MV, Jones MR, Rouillard AD, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90–7. doi: 10.1093/nar/gkw377
   PubMed Web of Science ®Google Scholar
• Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science (New York, N.Y.). 2018;359(6377):801–806. doi: 10.1126/science.aan5951.
   PubMed Web of Science ®Google Scholar
• Wang S, Xiong Y, Zhao L, et al. UCSCXenaShiny: an R/CRAN package for interactive analysis of UCSC xena data. Bioinformatics (Oxford, England). 2022;38(2):527–529.
   PubMed Web of Science ®Google Scholar
• Shankavaram UT, Varma S, Kane D, et al. CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics. 2009;10(1):277. doi: 10.1186/1471-2164-10-277
   PubMed Web of Science ®Google Scholar
• Gu P, Chen X, Xie R, et al. lncRNA HOXD-AS1 regulates proliferation and chemo-resistance of castration-resistant prostate cancer via recruiting WDR5. Mol Ther. 2017;25(8):1959–1973. doi: 10.1016/j.ymthe.2017.04.016
   PubMed Web of Science ®Google Scholar
• Bi J, Liu H, Dong W, et al. Circular RNA circ-ZKSCAN1 inhibits bladder cancer progression through miR-1178-3p/p21 axis and acts as a prognostic factor of recurrence. Mol cancer. 2019;18(1):133. doi: 10.1186/s12943-019-1060-9
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genet. 2019;51(2):202–206. doi: 10.1038/s41588-018-0312-8
   PubMed Web of Science ®Google Scholar
• Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility, nature reviews. Mol Cell Biol. 2005;6(1):56–68. doi: 10.1038/nrm1549
   Google Scholar
• Le Clainche C, Carlier MF. Regulation of actin assembly associated with protrusion and adhesion in cell migration. Physiol Rev. 2008;88(2):489–513. doi: 10.1152/physrev.00021.2007
   PubMed Web of Science ®Google Scholar
• Hardie DG. AMPK: positive and negative regulation, and its role in whole-body energy homeostasis. Curr Opinion Cell Biol. 2015;33:1–7. doi: 10.1016/j.ceb.2014.09.004
   PubMed Web of Science ®Google Scholar
• Hochreiter-Hufford A, Ravichandran KS. Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion. Cold Spring Harbor Perspect Biol. 2013;5(1):a008748. doi: 10.1101/cshperspect.a008748
   PubMed Web of Science ®Google Scholar
• Balda MS, Matter K. Tight junctions at a glance. J Cell Sci. 2008;121(Pt 22):3677–3682. doi: 10.1242/jcs.023887
   PubMed Web of Science ®Google Scholar
• Gardel ML, Schneider IC, Aratyn-Schaus Y, et al. Mechanical integration of actin and adhesion dynamics in cell migration, annual review of cell and developmental biology 26. Annu Rev Cell Dev Biol. 2010;26(1):315–333. doi: 10.1146/annurev.cellbio.011209.122036
   PubMedGoogle Scholar
• Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis, nature reviews. Mol Cell Biol. 2012;13(4):251–262. doi: 10.1038/nrm3311
   Google Scholar
• Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells, molecular cancer research. MCR. 2010;8(5):629–642. doi: 10.1158/1541-7786.MCR-10-0139
   Google Scholar
• Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Investig. 2007;117(5):1137–1146. doi: 10.1172/JCI31405
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nature Med. 2013;19(11):1423–1437. doi: 10.1038/nm.3394
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi: 10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262. doi: 10.1016/j.celrep.2016.12.019
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs, nature reviews. Nat Rev Cancer. 2004;4(4):253–265. doi: 10.1038/nrc1317
   PubMed Web of Science ®Google Scholar
• Bollag G, Hirth P, Tsai J, et al. Nolop, clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596–599. doi: 10.1038/nature09454
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208. doi: 10.1038/nm.3048
   PubMed Web of Science ®Google Scholar